STOCKSCOPE

Greatland Resources (ASX: GGP): $289m Cash Flow, but Can Havieron Deliver the Next Growth Phase?

Alison Elzayed

Alison Elzayed

Business & Finance Writer | StockScope

Published:26 Oct 2026
Greatland Resources (ASX: GGP): $289m Cash Flow, but Can Havieron Deliver the Next Growth Phase?

Greatland Resources (ASX: GGP) generated A$289 million in operating cash flow during the September quarter, while construction formally began at its Havieron gold-copper project. The combination strengthens the growth story, but the bigger question is whether Greatland can develop its next mine without compromising the cash generation that currently underpins its business.

The numbers tell two stories

  • Production: 70,131 ounces of gold and 2,927 tonnes of copper.
  • Revenue: A$485 million from gold and copper sales.
  • Operating cash flow: A$289 million for the quarter.
  • Cash balance: A$1.314 billion, with no drawn debt.
  • FY27 guidance: 260,000 to 300,000 ounces of gold at all-in sustaining costs of A$2,900 to A$3,330 an ounce.

Havieron changes the growth equation

Greatland's September quarter report, released on 26 October 2026, highlights the challenge of managing a producing mine while developing another major asset.

Its Telfer operation delivered strong processing throughput, 85.1% gold recoveries and record open-pit material movement. Underground development also reached 2,021 metres, supporting efforts to extend the mine's operating potential.

However, the more consequential development may be at Havieron, located about 45km east of Telfer. Following receipt of the required secondary approvals, construction formally commenced during September, with earthworks, evaporation ponds and underground decline development progressing.

Using Telfer's existing processing infrastructure to treat Havieron ore could help reduce the need to build an entirely separate processing operation. First gold from Havieron is expected in FY29, making execution over the next two years particularly important.

The cost of growth matters

Greatland's financial position gives it considerable flexibility. Its September quarter cash balance increased by A$25 million despite A$100 million in tax instalments and substantial growth expenditure.

The catch is that the development programme is becoming increasingly capital-intensive. FY27 guidance includes A$365 million to A$435 million for Havieron and A$315 million to A$335 million for Telfer growth projects.

These commitments will compete with operating requirements for cash. Gold production is also expected to be second-half weighted, while December brings an anticipated additional FY26 tax payment of approximately A$155 million.

What Greatland is doing now

Alongside Havieron construction, Greatland is advancing Telfer's underground opportunities, upgrading infrastructure and drilling to improve its resource base. It spent A$96.7 million on growth and capitalised exploration during the September quarter, including A$45.2 million at Havieron.

Insight: Can cash generation fund the next mine?

We see Greatland's strongest advantage as its ability to fund development from an established producing operation rather than relying entirely on fresh equity. However, quarterly operating cash flow is not the same as free cash flow after capital expenditure, taxes and other commitments. The key measure is whether Telfer can sustain production and margins while Havieron advances without materially eroding liquidity or forcing additional borrowing.

The next test is execution

Greatland enters FY27 with substantial cash reserves, an operating gold-copper business and a major development project under construction. Yet the combination also increases delivery risk and capital demands.

The next quarterly update should reveal whether production remains on track, costs stay within guidance and Havieron progresses against its construction schedule. The critical question is whether Greatland can turn today's strong cash generation into a longer-life, multi-mine business before development spending begins to weigh more heavily on its finances.

Alison Elzayed

Alison Elzayed

(Business & Finance Writer | StockScope)

Alison Elzayed is an experienced business and financial writer with more than 10 years of experience in the publishing industry, having previously worked as an author with Bloomsbury Publishing, specialising in business and finance. Throughout her career, Alison has developed a strong understanding of financial markets, corporate developments, economic trends and investment-related topics. Her background in financial publishing has equipped her with the ability to research complex subjects and communicate them in a clear, accurate and engaging manner.

DisclaimerInformation on Stockscope is general in nature and does not constitute financial product advice. It does not take into account your personal objectives, financial situation or needs. Seek independent advice from a qualified financial adviser before making an investment decision. Stockscope and its affiliates do not guarantee the accuracy or completeness of information published on this website. To the extent permitted by law, they accept no liability for any claim, loss or damage arising from its use or reliance on it. Stockscope and its associates may have commercial relationships with companies featured on this website, hold securities in those companies, or receive commissions in connection with capital raisings.

Continue Reading

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore
Market Briefings
Market Briefings

ASX Weathers Wall Street's AI Rout, but Three Market Risks Are Becoming Harder to Ignore

Australian equities: what moved the ASX 200? Australian shares finished lower on Friday, 6 November, as the technology-led sell-off on Wall Street spread across global markets. The ASX 200...

Mark ElzayedMark Elzayed•
Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test
Biotech & Health
Biotech & Health

Epiminder (ASX: EPI) Expands FDA Clearance as $65 Million Cash Reserve Faces a Crucial Commercial Test

Epiminder Limited ASX: EPI has expanded the US market for its epilepsy monitoring technology following a significant regulatory clearance, strengthening its commercial prospects ahead of a p...

Danny AadDanny Aad•
Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?
Mining
Mining

Asara Resources (ASX: AS1) Hits 38m at 2.1g/t Gold: Could Sogosogoba Unlock Kada's Next Growth Phase?

A 38-metre gold intersection grading 2.1 grams per tonne has given Asara Resources Limited ASX: AS1 an encouraging exploration result beyond its established Massan deposit in Guinea. The dis...

Alison ElzayedAlison Elzayed•
Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?
Mining
Mining

Alvo Minerals (ASX: ALV) Expands Rare Earth Discovery Across 6.5km², but Can It Deliver Economic Value?

Alvo Minerals Limited ASX: ALV has extended rare earth mineralisation approximately 2 kilometres beyond previously tested areas at its Boa Vista prospect in Brazil, strengthening the explora...

Alison ElzayedAlison Elzayed•
Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet
Mining
Mining

Avenira Limited (ASX: AEV) Raises $48.9 Million as Wonarah Phosphate Project Faces Its Biggest Test Yet

Avenira Limited ASX: AEV has reached a significant financing milestone, with its $48.9 million rights issue providing fresh capital to advance the Wonarah Phosphate Project in the Northern T...

Alison ElzayedAlison Elzayed•
Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?
Biotech & Health
Biotech & Health

Mayne Pharma Group (ASX: MYX) Unveils $55.5 Million Sale, but Can Its US Business Deliver Stronger Profits?

Mayne Pharma Group Limited ASX: MYX is taking a decisive step towards becoming a US-focused pharmaceutical company, agreeing to sell its international operations for $55.5 million. The tran...

Danny AadDanny Aad•
Loading more stories...